BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15269783)

  • 1. The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells.
    Srinivasan RS; Nesbit JB; Marrero L; Erfurth F; LaRussa VF; Hemenway CS
    Leukemia; 2004 Aug; 18(8):1364-72. PubMed ID: 15269783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells.
    Palermo CM; Bennett CA; Winters AC; Hemenway CS
    Leuk Res; 2008 Apr; 32(4):633-42. PubMed ID: 17875318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele.
    Kowarz E; Burmeister T; Lo Nigro L; Jansen MW; Delabesse E; Klingebiel T; Dingermann T; Meyer C; Marschalek R
    Leukemia; 2007 Jun; 21(6):1232-8. PubMed ID: 17410185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
    Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
    Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular findings in childhood leukemia in Brazil: high frequency of MLL-ENL Fusion/t(11;19) in infant leukemia.
    Marques EA; Neves L; Fonseca TC; Lins MM; Pedrosa F; Lucena-Silva N
    J Pediatr Hematol Oncol; 2011 Aug; 33(6):470-4. PubMed ID: 21436736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression.
    Dou L; Zheng D; Li J; Li Y; Gao L; Wang L; Yu L
    Oncogene; 2012 Jan; 31(4):507-17. PubMed ID: 21706045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor.
    Srinivasan RS; de Erkenez AC; Hemenway CS
    Oncogene; 2003 May; 22(22):3395-406. PubMed ID: 12776190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?
    Sanders DS; Muntean AG; Hess JL
    Leuk Res; 2011 Mar; 35(3):299-300. PubMed ID: 20952059
    [No Abstract]   [Full Text] [Related]  

  • 9. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
    Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
    Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.
    Bennett CA; Winters AC; Barretto NN; Hemenway CS
    Leuk Res; 2009 Jul; 33(7):937-47. PubMed ID: 19232721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcript.
    Imamura T; Morimoto A; Ikushima S; Kakazu N; Hada S; Tabata Y; Yagi T; Inaba T; Hibi S; Sugimoto T; Imashuku S
    Leukemia; 2002 Nov; 16(11):2302-8. PubMed ID: 12399976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation.
    Gaussmann A; Wenger T; Eberle I; Bursen A; Bracharz S; Herr I; Dingermann T; Marschalek R
    Oncogene; 2007 May; 26(23):3352-63. PubMed ID: 17130830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL.
    Kumar AR; Yao Q; Li Q; Sam TA; Kersey JH
    Leuk Res; 2011 Mar; 35(3):305-9. PubMed ID: 20869771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of AF4 wild-type and AF4.MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?
    Bursen A; Moritz S; Gaussmann A; Moritz S; Dingermann T; Marschalek R
    Oncogene; 2004 Aug; 23(37):6237-49. PubMed ID: 15221006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
    Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute megakaryoblastic leukemia in a child with the MLL-AF4 fusion gene.
    Takita J; Motomura A; Koh K; Ida K; Taki T; Hayashi Y; Igarashi T
    Eur J Haematol; 2009 Aug; 83(2):149-53. PubMed ID: 19459927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
    Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
    Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLL fusion partners AF4 and AF9 interact at subnuclear foci.
    Erfurth F; Hemenway CS; de Erkenez AC; Domer PH
    Leukemia; 2004 Jan; 18(1):92-102. PubMed ID: 14603337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
    Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
    Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
    Xia ZB; Popovic R; Chen J; Theisler C; Stuart T; Santillan DA; Erfurth F; Diaz MO; Zeleznik-Le NJ
    Proc Natl Acad Sci U S A; 2005 Sep; 102(39):14028-33. PubMed ID: 16169901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.